| Old Articles: <Older 1271-1280 Newer> |
|---|
 |
The Motley Fool
June 30, 2004
Bill Mann |
Thoratec's Palpitations Are the company's heart devices unwanted, or just being adopted more slowly than expected? Several Wall Street analysts responded by slashing their ratings on the firm.   |
The Motley Fool
June 30, 2004
Rich Duprey |
Leeches Get Blood Flowing A French firm gets FDA approval to market the creatures as a medical device. |
The Motley Fool
June 30, 2004
Alyce Lomax |
A Monster Drug for Lilly? The drug giant files a new drug application (NDA) for its experimental new drug for diabetics. |
The Motley Fool
June 29, 2004
Rich Smith |
Thomson's Patently Good Buy Thomson will purchase Information Holdings, a provider of intellectual property information. The acquisition would significantly boost Thomson's scientific and health-care business. |
The Motley Fool
June 29, 2004
Charly Travers |
Antegren Gets Priority Review The FDA steps up the drug's time line for approval. |
BusinessWeek
July 5, 2004
Michael Arndt |
High Tech -- And Handcrafted Despite a recent recall, medical-products maker Medtronic sets the quality standard for heart care. |
BusinessWeek
July 5, 2004 |
The Heart Is Just the Start CEO Art Collins explains how Medtronics is moving into treating spinal injuries, neurological disorders, diabetes, and more. |
The Motley Fool
June 28, 2004
Jeff Hwang |
Watson Pharmaceuticals Tumbles The generic drug business at Watson Pharmaceuticals is still going strong; it's the branded products that are causing trouble. |
The Motley Fool
June 28, 2004
Alyce Lomax |
Is Amgen's Engine Stalled? Amgen slipped in today's trading session after it said that an experimental drug for advanced cases of Parkinson's disease didn't meet its primary end point in a recent clinical trial. |
IndustryWeek
July 1, 2004
Karen M. Kroll |
Life On The Island The life sciences industry taps Puerto Rico for tax breaks, educated workforce. |
| <Older 1271-1280 Newer> Return to current articles. |
